Time‐varying effects of sodium‐glucose cotransporter‐2 inhibitors in patients with heart failure: An updated meta‐analysis

Journal of Evidence-Based MedicineEarly View LETTER Time-varying effects of sodium-glucose cotransporter-2 inhibitors in patients with heart failure: An updated meta-analysis Xinyu Zou, Xinyu Zou Department of Endocrinology and Metabolism, MAGIC China Center, West China Hospital of Sichuan University, Chengdu, ChinaSearch for more papers by this authorQingyang Shi, Qingyang Shi Department of Endocrinology and Metabolism, MAGIC China Center, West China Hospital of Sichuan University, Chengdu, China Faculty of Science and Engineering, University of Groningen, Groningen, the NetherlandsSearch for more papers by this authorSheyu Li, Corresponding Author Sheyu Li [email protected] orcid.org/0000-0003-0060-0287 Department of Endocrinology and Metabolism, MAGIC China Center, West China Hospital of Sichuan University, Chengdu, China Correspondence Sheyu Li, Department of Endocrinology and Metabolism, MAGIC China Centre, West China Hospital of Sichuan University, Chengdu 610041, China. Email: [email protected]Search for more papers by this author Xinyu Zou, Xinyu Zou Department of Endocrinology and Metabolism, MAGIC China Center, West China Hospital of Sichuan University, Chengdu, ChinaSearch for more papers by this authorQingyang Shi, Qingyang Shi Department of Endocrinology and Metabolism, MAGIC China Center, West China Hospital of Sichuan University, Chengdu, China Faculty of Science and Engineering, University of Groningen, Groningen, the NetherlandsSearch for more papers by this authorSheyu Li, Corresponding Author Sheyu Li [email protected] orcid.org/0000-0003-0060-0287 Department of Endocrinology and Metabolism, MAGIC China Center, West China Hospital of Sichuan University, Chengdu, China Correspondence Sheyu Li, Department of Endocrinology and Metabolism, MAGIC China Centre, West China Hospital of Sichuan University, Chengdu 610041, China. Email: [email protected]Search for more papers by this author First published: 11 March 2024 https://doi.org/10.1111/jebm.12597Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Supporting Information Filename Description jebm12597-sup-0001-TableS1.docx32.8 KB Supporting Information Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. REFERENCES 1Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2022; 118(17), 3272–3287. 10.1093/cvr/cvac013 CASWeb of Science®Google Scholar 2Shi Q, Nong K, Vandvik PO, et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2023; 381:e074068. PubMedGoogle Scholar 3Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022; 400(10354), 757–767. 10.1016/S0140-6736(22)01429-5 CASPubMedWeb of Science®Google Scholar 4Zou X, Shi Q, Vandvik PO, et al. Sodium-glucose cotransporter-2 inhibitors in patients with heart failure : a systematic review and meta-analysis. Ann Intern Med. 2022; 175(6), 851–861. 10.7326/M21-4284 PubMedGoogle Scholar 5Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022; 387(12), 1089–1098. 10.1056/NEJMoa2206286 PubMedWeb of Science®Google Scholar 6Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372: n71. 10.1136/bmj.n71 PubMedGoogle Scholar 7Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2021; 21(1), 111. 10.1186/s12874-021-01308-8 PubMedWeb of Science®Google Scholar 8Shen Y, Shi Q, Zou X, et al. Time-dependent risk of fracture in adults with type 2 diabetes receiving anti-diabetic drug: A one-stage network meta-analysis. Diabetes Metab Res Rev. 2024; 40(2), e3780. 10.1002/dmrr.3780 CASPubMedWeb of Science®Google Scholar 9Atal I, Porcher R, Boutron I, Ravaud P. The statistical significance of meta-analyses is frequently fragile: definition of a fragility index for meta-analyses. J Clin Epidemiol. 2019; 111: 32–40. 10.1016/j.jclinepi.2019.03.012 PubMedWeb of Science®Google Scholar 10Spertus JA, Jones PG, Sandhu AT, Arnold SV. Interpreting the Kansas City cardiomyopathy questionnaire in clinical trials and clinical care: jACC state-of-the-art review. J Am Coll Cardiol. 2020; 76(20), 2379–2390. 10.1016/j.jacc.2020.09.542 PubMedWeb of Science®Google Scholar 11Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020; 383(15), 1413–1424. 10.1056/NEJMoa2022190 CASPubMedWeb of Science®Google Scholar 12 Nuffield Department of Population Health Renal Studies Group. SGLT2 inhibitor meta-analysis cardio-renal trialists' consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022; 400(10365), 1788–1801. 10.1016/S0140-6736(22)02074-8 PubMedWeb of Science®Google Scholar 13McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023; 44(37), 3627–3639. 10.1093/eurheartj/ehad195 CASPubMedWeb of Science®Google Scholar 14Vaduganathan M, Claggett BL, Jhund P, et al. Time to clinical benefit of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified secondary analysis of the DELIVER randomized clinical trial. JAMA Cardiol. 2022; 7(12), 1259–1263. 10.1001/jamacardio.2022.3750 PubMedGoogle Scholar 15Lawson CA, Zaccardi F, Squire I, et al. 20-year trends in cause-specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis: a population-based study. Lancet Public Health. 2019; 4(8), e406–e420. 10.1016/S2468-2667(19)30108-2 PubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation